The management of postsurgical pain with patient-controlled analgesia pumps may be safe, as indicated by a low rate of device-related error.
The FDA Digital Health Software Precertification Program represents a feasible solution to regulate software classified as a medical device.
The FDA has approved 2 new migraine treatment devices to stop and prevent migraine attacks in adults.
Researchers are urging legislators to assign ICD codes to all medical devices, which could help identify device-related adverse effects more accurately.
About half of U.S. doctors received payments from the pharmaceutical and medical device industries in 2015.
Bayer announced the launch of Aleve Direct Therapy, a pain relief device.
Clinical Pain Advisor Articles
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Electroacupuncture May Help Reduce Opioid Use in Chronic Musculoskeletal Pain
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Opioid Use Disorder Prevalence at Delivery on the Rise in the US, According to CDC
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Pharmacologically Induced Headache Accompanied by Dilated Cephalic Vessels
- IV Lidocaine May Be Safe, Efficacious for Pediatric Status Migraine
- Gray Matter Changes in Migraine Associated With Clinical Characteristics